These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 29264930)

  • 1. Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.
    Krumme AA; Pawar A; Schneeweiss S; Glynn RJ; Choudhry NK; Kulldorff M; Ortiz AS; Avorn J; Gagne JJ
    J Comp Eff Res; 2018 Jan; 7(1):57-66. PubMed ID: 29264930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new oral anticoagulants: Reasonable alternatives to warfarin.
    Roca B; Roca M
    Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
    Robertson L; Kesteven P; McCaslin JE
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010957. PubMed ID: 26636644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulants: What is new and what is the standard?
    Lesko LJ
    Clin Pharmacol Ther; 2016 Aug; 100(2):126-8. PubMed ID: 27197625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
    PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target-specific oral anticoagulants and the hospitalist.
    Deitelzweig S; Amin A
    Hosp Pract (1995); 2015; 43(1):1-12. PubMed ID: 25559350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of pulmonary embolism.
    Décousus H; Mismetti P; Couturaud F; Ageno W; Bauersachs R
    Presse Med; 2015 Dec; 44(12 Pt 2):e393-9. PubMed ID: 26547678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin for Patients With Left Ventricular Thrombus: A Systematic Review and Meta-Analysis.
    Gue YX; Spinthakis N; Egred M; Gorog DA; Farag M
    Am J Cardiol; 2021 Mar; 142():147-151. PubMed ID: 33359200
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.
    Gao JH; Chu XC; Wang LL; Ning B; Zhao CX
    Medicine (Baltimore); 2017 Oct; 96(40):e8059. PubMed ID: 28984761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I; Smith KJ; Zhang Y
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Not Available].
    Oldgren J
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512140
    [No Abstract]   [Full Text] [Related]  

  • 16. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
    Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
    Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
    Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S
    Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.
    Arachchillage DR; Besser M; Maclean R; Baglin T; van Veen JJ
    Thromb Res; 2016 Jul; 143():137-40. PubMed ID: 27244105
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
    Khorana AA; Noble S; Lee AYY; Soff G; Meyer G; O'Connell C; Carrier M
    J Thromb Haemost; 2018 Sep; 16(9):1891-1894. PubMed ID: 30027649
    [No Abstract]   [Full Text] [Related]  

  • 20. Overview of the new oral anticoagulants: opportunities and challenges.
    Yeh CH; Hogg K; Weitz JI
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.